In the last two decades, and thanks to a better understanding of the key role of the components involved in the inflammatory pathway, the inflammatory mediators TNF-α, IL-6, COX-2 and their upstream signal regulator NF-κB have become new promising anti-inflammatory therapy targets for the treatment of IBD [2]. Here, NFKB1 is linked to inflammatory bowel disease.